409 related articles for article (PubMed ID: 25096959)
1. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Ptaszynska A; Johnsson KM; Parikh SJ; de Bruin TW; Apanovitch AM; List JF
Drug Saf; 2014 Oct; 37(10):815-29. PubMed ID: 25096959
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Jabbour S; Seufert J; Scheen A; Bailey CJ; Karup C; Langkilde AM
Diabetes Obes Metab; 2018 Mar; 20(3):620-628. PubMed ID: 28950419
[TBL] [Abstract][Full Text] [Related]
4. Hypersensitivity Events, Including Potentially Hypersensitivity-Related Skin Events, with Dapagliflozin in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Mellander A; Billger M; Johnsson E; Träff AK; Yoshida S; Johnsson K
Clin Drug Investig; 2016 Nov; 36(11):925-933. PubMed ID: 27461213
[TBL] [Abstract][Full Text] [Related]
5. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Kohler S; Salsali A; Hantel S; Kaspers S; Woerle HJ; Kim G; Broedl UC
Clin Ther; 2016 Jun; 38(6):1299-1313. PubMed ID: 27085585
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
7. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF
J Diabetes Complications; 2013; 27(5):479-84. PubMed ID: 23806570
[TBL] [Abstract][Full Text] [Related]
8. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Matthaei S; Bowering K; Rohwedder K; Sugg J; Parikh S; Johnsson E;
Diabetes Obes Metab; 2015 Nov; 17(11):1075-84. PubMed ID: 26212528
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
[TBL] [Abstract][Full Text] [Related]
10. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
Kohler S; Zeller C; Iliev H; Kaspers S
Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
Parikh S; Wilding J; Jabbour S; Hardy E
Int J Clin Pract; 2015 Feb; 69(2):186-98. PubMed ID: 25438821
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Plosker GL
Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.
Araki E; Onishi Y; Asano M; Kim H; Yajima T
Diabetes Obes Metab; 2017 Apr; 19(4):562-570. PubMed ID: 27987240
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
Skolnik N; Bonnes H; Yeh H; Katz A
Postgrad Med; 2016 May; 128(4):356-63. PubMed ID: 27043045
[TBL] [Abstract][Full Text] [Related]
18. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.
Cahn A; Raz I; Bonaca M; Mosenzon O; Murphy SA; Yanuv I; Rozenberg A; Wilding JPH; Bhatt DL; McGuire DK; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Jermendy G; Hadjadj S; Langkilde AM; Sabatine MS; Wiviott SD; Leiter LA
Diabetes Obes Metab; 2020 Aug; 22(8):1357-1368. PubMed ID: 32239659
[TBL] [Abstract][Full Text] [Related]
19. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Wan Seman WJ; Kori N; Rajoo S; Othman H; Mohd Noor N; Wahab NA; Sukor N; Mustafa N; Kamaruddin NA
Diabetes Obes Metab; 2016 Jun; 18(6):628-32. PubMed ID: 26889911
[TBL] [Abstract][Full Text] [Related]
20. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
